Circio Holding ASA – Funding requested under additional financing commitment from Atlas
4 augusti, 10:57
Oslo, Norway 4 August 2025: Reference is made to the financing commitment provided by Atlas to fund the Company’s operations until the end of June 2025. The financing commitment has been extended to enable funding flexibility to the end of the fourth quarter 2025 (the “Additional Financing Commitment”).
The Company has by a notice of exercise requested Atlas to subscribe and pay for one additional tranche of convertible bonds, consisting of 11 convertible bonds with an aggregate principal amount equal to NOK 5,500,000. Atlas will be allocated these bonds under the terms and conditions of the Investment Agreement.
For further information, please contact:
Erik Digman Wiklund, CEO
Phone: +47 413 33 536
Email: erik.wiklund@circio.com
Lubor Gaal, CFO
Phone: +34 683 34 3811
Email: lubor.gaal@circio.com
About Circio
Buildingcircular RNA expression systems for enhanced gene and cell therapies
Circio Holding ASA is a biotechnology company developing powerful circular RNA vector expression technology for next generation nucleic acid medicine.
Circio has established a unique circular RNA (circRNA) vector expression technology for next generation RNA, DNA and viral therapeutics. The proprietary circVec platform is based on a modular genetic cassette design for efficient biogenesis of multifunctional circRNA inside cells. The circVec platform has applications in multiple therapeutic settings, including genetic medicine, cell therapy and chronic disease. It has demonstrated over 70-fold prolonged RNA half-life and up to 15-fold enhanced protein expression vs. conventional mRNA vector systems in vivo, and has the potential to become a new gold-standard protein expression technology. The circRNA R&D activities are being conducted by the wholly owned subsidiary Circio AB in Stockholm, Sweden.
In parallel, Circio is continuing to develop its legacy immuno-oncology program, TG01, through cost-efficient external academic and industry collaborations. TG01 targets RAS-mutated cancers and is being tested in two clinical trials in Norway and the USA. TG01 is a therapeutic peptide vaccine adjuvanted by STIMULON QS-21 licensed from Agenus Inc.
Ämnen i artikeln
Circio Holding ASA – Funding requested under additional financing commitment from Atlas
4 augusti, 10:57
Oslo, Norway 4 August 2025: Reference is made to the financing commitment provided by Atlas to fund the Company’s operations until the end of June 2025. The financing commitment has been extended to enable funding flexibility to the end of the fourth quarter 2025 (the “Additional Financing Commitment”).
The Company has by a notice of exercise requested Atlas to subscribe and pay for one additional tranche of convertible bonds, consisting of 11 convertible bonds with an aggregate principal amount equal to NOK 5,500,000. Atlas will be allocated these bonds under the terms and conditions of the Investment Agreement.
For further information, please contact:
Erik Digman Wiklund, CEO
Phone: +47 413 33 536
Email: erik.wiklund@circio.com
Lubor Gaal, CFO
Phone: +34 683 34 3811
Email: lubor.gaal@circio.com
About Circio
Buildingcircular RNA expression systems for enhanced gene and cell therapies
Circio Holding ASA is a biotechnology company developing powerful circular RNA vector expression technology for next generation nucleic acid medicine.
Circio has established a unique circular RNA (circRNA) vector expression technology for next generation RNA, DNA and viral therapeutics. The proprietary circVec platform is based on a modular genetic cassette design for efficient biogenesis of multifunctional circRNA inside cells. The circVec platform has applications in multiple therapeutic settings, including genetic medicine, cell therapy and chronic disease. It has demonstrated over 70-fold prolonged RNA half-life and up to 15-fold enhanced protein expression vs. conventional mRNA vector systems in vivo, and has the potential to become a new gold-standard protein expression technology. The circRNA R&D activities are being conducted by the wholly owned subsidiary Circio AB in Stockholm, Sweden.
In parallel, Circio is continuing to develop its legacy immuno-oncology program, TG01, through cost-efficient external academic and industry collaborations. TG01 targets RAS-mutated cancers and is being tested in two clinical trials in Norway and the USA. TG01 is a therapeutic peptide vaccine adjuvanted by STIMULON QS-21 licensed from Agenus Inc.
Ämnen i artikeln
Aktieråd
-992x558.webp&w=3840&q=75)
Analys
Bostadsmarknaden
Aktieråd
Mest läst
Analys
Bostadsmarknaden
Senaste nytt
Marknadsöversikt
OMX Stockholm 30
1 DAG %
0,39%
Senast
2 562,75
1 mån
Loading market data...
Privatekonomi med Placeras expert
Affärsvärlden
